ADVFN US – Market Content Editor
-
Dow Jones, S&P, Nasdaq, Futures, Wall Street Set to Open Higher as Nvidia Strengthens Tech Momentum
U.S. stock futures were pointing to a higher open on Monday, suggesting Wall Street may build on last week’s positive momentum as strong gains in Nvidia (NASDAQ:NVDA) lift sentiment across the technology sector. The AI chipmaker climbed 2.2% in premarket trading after Microsoft (NASDAQ:MSFT) confirmed it had received export licenses from the Trump administration to…
-
Kontoor Brands Beats Q3 Profit Forecasts and Lifts Full-Year Guidance
Kontoor Brands, Inc. (NYSE:KTB) reported third-quarter earnings that surpassed expectations on Monday, as strong execution and an expanded brand portfolio helped offset a modest revenue miss. The company also raised its full-year outlook, citing continued momentum across key categories. The parent of Wrangler, Lee, and Helly Hansen posted adjusted earnings of $1.44 per share, topping…
-
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results
Caribou Biosciences Inc. (NASDAQ:CRBU) shares skyrocketed 100% on Monday after the company released promising Phase 1 clinical data for its CB-011 therapy in patients with relapsed or refractory multiple myeloma. The CRISPR-based genome-editing company reported a 92% overall response rate and a 75% complete response rate or better among 12 patients treated with the recommended…
-
Stardust Power Shares Jump 15% After Securing Long-Term U.S. Lithium Supply Deal
Stardust Power Inc. (NASDAQ:SDST) shares soared 15% on Monday after the company announced a strategic supply agreement with Mandrake Resources Limited, ensuring access to 7,500 metric tons per year of lithium chloride from Mandrake’s Utah Lithium Project. The companies signed a non-binding Letter of Intent outlining a 12-year supply arrangement with an optional six-year extension,…
-
BioNTech Shares Climb as Strong Revenue Growth Offsets Profit Miss
BioNTech SE (NASDAQ:BNTX) shares rose 2.9% on Monday after the German biotech firm reported third-quarter revenue that far exceeded expectations, even though it posted a loss where analysts had forecast a profit. The company also raised its full-year 2025 revenue outlook, citing stronger-than-expected results from its collaboration with Bristol Myers Squibb (NYSE:BMY). For the third…
-
Kenvue Shares Soar 22% After $48.7 Billion Merger Deal With Kimberly-Clark
Kenvue (NYSE:KVUE) shares surged more than 22% in premarket trading Monday after the U.S. consumer health company reported better-than-expected third-quarter results and revealed plans to be acquired by Kimberly-Clark (NASDAQ:KMB) in a $48.7 billion cash-and-stock deal. For the third quarter, Kenvue earned $0.28 per share, topping analyst estimates of $0.26, while revenue came in at…
-
Kimberly-Clark Shares Drop as $48.7 Billion Kenvue Acquisition Sparks Legal Concerns
Kimberly-Clark (NASDAQ:KMB) shares tumbled more than 13% on Monday after the company announced a major cash-and-stock acquisition of Kenvue (NYSE:KVUE), valuing the consumer health firm at an enterprise value of roughly $48.7 billion. Under the agreement, Kenvue shareholders will receive $3.50 per share in cash and 0.14625 shares of Kimberly-Clark for each Kenvue share held.…
-
Freshpet Shares Surge After Q3 Earnings Blow Past Expectations
Freshpet, Inc. (NASDAQ:FRPT) shares climbed 5.3% on Monday after the pet food company reported third-quarter results that sharply outperformed Wall Street estimates, supported by robust sales growth and improved profitability. The company posted adjusted earnings of $1.86 per share, far exceeding the consensus forecast of $0.43. Revenue rose 14% year-on-year to $288.8 million, topping analyst…
-
uniQure Shares Collapse 75% After FDA Reverses Position on Huntington’s Therapy
uniQure N.V. (NASDAQ:QURE) shares plunged 75% on Monday after the biotech company announced a major regulatory setback for its experimental Huntington’s disease gene therapy, AMT-130. The Netherlands-based firm revealed that the U.S. Food and Drug Administration (FDA) no longer agrees that data from Phase I/II trials, when compared with external control datasets, would be sufficient…
-
Beyond Meat Delays Q3 Earnings Release to Complete Impairment Review
Beyond Meat (NASDAQ:BYND) has delayed the release of its third-quarter financial results to November 11, citing the need for additional time to finalize an accounting review. The company said it is assessing a material non-cash impairment charge tied to certain long-lived assets. The plant-based meat company explained that it requires more time and resources to…